Optimer Pharma (OPTR) Stock Slips on Numerous Analyst Downgrades
More News related to OPTR
- Ladenburg Thalmann Downgrades Optimer Pharmaceuticals (OPTR) to Neutral
- Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform
- Optimer Pharmaceuticals (OPTR) Posts Q3 Loss of $0.28, 9c Better than Views
- Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Optimer Pharma (OPTR) Presented New Data for Fidaxomicin's Phase 3
Shares of Optimer Pharmaceuticals (Nasdaq: OPTR) have fallen sharply today following news early yesterday that the results from a Phase 3 trial of fidaxomicin were presented at the 19th annual European Congress of Clinical Methodology and Infectious Diseases. The stock most recently traded at $10.83, down more than 7% from Optimer's close on Friday of last week.
Also creating downside today, the stock was downgraded this morning by analysts at Needham & Co., Ladenburg Thalmann and JMP Securities. Needham cut the stock from Buy to Hold, while Ladenburg moved the stock from Buy to Neutral. JMP downgraded Optimer from Market Outperform to Market Perform.
To see all the analyst calls on shares of Optimer, click here or go to http://www.streetinsider.com/stock_lookup_news.php?q=optr&type=analyst.
Related Categories
DowngradesStocks Mentioned
+0.32Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
